A new anticoagulant therapy aimed at inhibition and rapid reversal of the factor IXa pathway is safe and feasible in patients undergoing elective percutaneous coronary intervention (PCI), according to a pilot study published online July 26, 2010, ahead of print in Circulation. The findings offer the prospect of improved control over the twin risks of thrombosis and bleeding compared with currently used agents.
